CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
ILLUMINATE focuses on improving cancer treatment through enhanced imaging and sustainable production of Lutetium-177, a key radioisotope. The project aims to optimize patient outcomes and increase the availability of theranostic therapies in oncology.
Selective targeting of therapy with antibody-radioisotope combinations have led to major advances in treating cancers that are resistant to common therapies, such as castrate-resistant prostate cancer.
Adding Lutetium-177-PSMA (Lu-177-PSMA) to standard care significantly prolongs survival.
However, the increased use of Lu-177-based therapies has resulted in an increased demand for this isotope, leading to shortage risks.In addition, despite the success of Lu-177-treatment, ~30% of patients do no…
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Finland, Turku
Type: Research institute
Activity type: Research Organisations
SME: No
PHILIPS MEDICAL SYSTEMS NEDERLAND
Netherlands, Best
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Germany, Hamburg
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Italy, Napoli
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
